Natera (NTRA) Stock Dips After Co-Founder Sheena Jonathan Sells $909K Worth of Shares

Sheena Jonathan, co-founder and director of Natera, Inc. (NASDAQ:NTRA), has executed a notable sale of company stock, drawing attention from investors and analysts alike.

Sheena Jonathan, co-founder and director of Natera, Inc. (NASDAQ:NTRA), recently made headlines with a notable sale of company stock, according to a Form 4 filed with the U.S. Securities and Exchange Commission. On January 2, 2025, Jonathan sold shares totaling approximately $909,125, a transaction that has piqued the interest of investors and analysts alike.

The sales, executed in multiple transactions, involved varying share prices ranging from $158.71 to $160.70. Following these transactions, Jonathan retains a substantial stake in Natera, with direct ownership of 254,372 shares and indirect ownership of 44,782 shares through the Caraluna 1 and Caraluna 2 Trusts.

This activity comes as Natera’s stock approaches its 52-week high of $175.63, having surged an impressive 180% over the past year. The company's strong financial performance has been a key driver of this rally, with InvestingPro bestowing a “GOOD” financial health rating on the biotechnology firm.

Natera recently reported record Q3 revenue of $439.8 million, a remarkable 64% year-over-year increase. The company's oncology division also achieved a significant milestone, conducting 137,000 tests in the third quarter alone, a 54% jump compared to the previous year.

These metrics highlight the company's operational strength, even as market valuation concerns continue to be a topic of discussion. Several analyst firms have maintained favorable ratings on Natera's stock, reflecting confidence in its continued growth trajectory.

For instance, TD Cowen has a "buy" rating on the stock with a price target of $200, while Baird has a "neutral" rating and a price target of $170. Jefferies also has a "buy" rating on the stock with a price target of $225.

While Natera enjoys financial success, the company is also actively engaged in several significant legal disputes. Most notably, it has expanded its patent infringement litigation against NeoGenomics (NASDAQ:NEO), Inc. by adding another patent to the ongoing lawsuit.

The outcome of this litigation could further solidify Natera's intellectual property standing in the competitive biotechnology space. However, not all legal battles have gone in Natera's favor.

The company faced a setback in a false advertising lawsuit against Guardant Health (NASDAQ:GH) when the court ruled against Natera. Despite this, the company plans to request a reversal of the ruling, indicating its commitment to protecting its reputation and market positioning.

In a related development, Natera has amended its agreement with Executive Chairman Dr. Rabinowitz to ensure his continued leadership under revised terms, as noted in a separate SEC filing.

This move comes after Rabinowitz expressed his intention to step down from his role at Natera following the company's annual meeting in May 2024. However, the company has since engaged in discussions with Rabinowitz regarding his continued leadership, leading to this amendment.

Sheena Jonathan's recent stock sale, executed near the company's all-time high, aligns with a broader trend of insiders capitalizing on strong market performance. While such moves can sometimes raise questions, the use of a Rule 10b5-1 trading plan underscores transparency and adherence to regulatory guidelines.

As Natera balances its financial achievements with legal challenges, investor sentiment remains optimistic. The stock's strong upward trajectory and bullish analyst outlook indicate that the market sees significant potential for continued success.